

۱. بررسی ارتباط لنفوپنی با پیش آگهی کوتاه مدت بیماران مبتلا به سپسیس مراجعه کننده به اورژانس بیمارستان دکتر شریعتی

1. Chung KP, Chang HT, Lo SC, Chang LY, Lin SY, Cheng A, et al. Severe lymphopenia is associated with elevated plasma interleukin-15 levels and increased mortality during severe sepsis. *Shock*. 2015;43(6):569-75.
2. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. *Shock*. 2014;42(5):383-91.
3. Chien y-c, Chung K-P, Cheng j-s, Chang H-T, Yu c-j. Lymphopenia Is Associated With Worse Outcome In Patients With Severe Sepsis 2012. A5992-A p.
4. Rajan G, Sleigh JW. Lymphocyte counts and the development of nosocomial sepsis. *Intensive care medicine*. 1997;23(11):1187.
5. Wyllie DH, Bowler IC, Peto TE. Relation between lymphopenia and bacteraemia in UK adults with medical emergencies. *Journal of clinical pathology*. 2004;57(9):950-5.
6. Inoue S, Suzuki-Utsunomiya K, Okada Y, Taira T, Iida Y, Miura N, et al. Reduction of immunocompetent T cells followed by prolonged lymphopenia in severe sepsis in the elderly. *Critical care medicine*. 2013;41(3):810-9.
7. Schoenberg MH, Weiss M, Radermacher P. Outcome of patients with sepsis and septic shock after ICU treatment. *Langenbeck's archives of surgery*. 1998;383(1):44-8.
8. Nasa P, Juneja D, Singh O, Dang R, Arora V. Severe sepsis and its impact on outcome in elderly and very elderly patients admitted in intensive care unit. *Journal of intensive care medicine*. 2012;27(3):179-83.
9. Cheung WK, Chau LS, Mak, II, Wong MY, Wong SL, Tiwari AF. Clinical management for patients admitted to a critical care unit with severe sepsis or septic shock. *Intensive & critical care nursing*. 2015;31(6):359-65.
10. Monserrat J, de Pablo R, Reyes E, Diaz D, Barcenilla H, Zapata MR, et al. Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients. *Critical care*. 2009;13(1):R26.
11. Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE, et al. The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states. *Critical care*. 2010;14(1):R19.
12. Monserrat J, de Pablo R, Diaz-Martin D, Rodriguez-Zapata M, de la Hera A, Prieto A, et al. Early alterations of B cells in patients with septic shock. *Critical care*. 2013;17(3):R105.

۲. قلب و بیماری لوپوس اریتماتوز سیستمیک

1. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. 2012;64(8):2677-86.
2. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. *Semin Arthritis Rheum*. 2010;39(4):257-68.
3. Nakashima CAK, Galhardo AP, Silva JFM, Fiorenzano GR, Santos ABS, Leite MFS, et al. Incidência e aspectos clínico-laboratoriais do lúpus eritematoso sistêmico em cidade do sul do Brasil. *Rev Bras Reumatol*. 2021;51(3):231-9.
4. Ishimori ML, Martin R, Berman DS, Goykhman P, Shaw LJ, Shufelt CM, et al. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. *JACC Cardiovasc Imaging*. 2011;4(1):27-33.
5. Patino Giraldo S, González Naranjo LA, Vasquez Duque GM, Restrepo Escobar M. Heart disease characteristics in patients with systemic lupus erythematosus. *Iatreia*. 2013;26(4):447-56.
6. Clarke AE, Urowitz MB, Monga N, Hanly JG. Costs associated with severe and non-severe SLE in Canada. *Arthritis Care Res (Hoboken)*. 2014 Sep 3. Epub ahead of print.
7. Teixeira PC, Ferber P, Vuilleumier N, Cutler P. Biomarkers for cardiovascular risk assessment in autoimmune diseases. *Proteomics Clin Appl*. 2015;9(1-2):48-57.
8. Arnaud L, Mathian A, Bruckert E, Amoura Z. Assessing the cardiovascular risk in patients with systemic lupus erythematosus. *Rev Med Interne*. 2014;35(11):723-9.
9. Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. *J Rheumatol*. 2014;41(4):680-7.
10. Appenzeller S, Pineau CA, Clarke AE. Acute lupus myocarditis: clinical features and outcome. *Lupus*. 2011;20(9):981-8.
11. Chen PY, Chang CH, Hsu CC, Liao YY, Chen KT. Systemic lupus erythematosus presenting with cardiac symptoms. *Am J Emerg Med*. 2014;32(9):1117-9.

12. Liu L, Zhang T, Ye Y, Zhang S, Chen L. [Analysis of traditional cardiovascular risk factors in patients with systemic lupus erythematosus]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2014;42(9):753-8.
13. Parker B, Bruce I. SLE and metabolic syndrome. *Lupus*. 2013;22(12):1259-66.
14. Ciccone MM, Zito A, Dentamaro I, Vestito D, Scicchitano P, Iacoviello M, et al. [Vitamin D deficiency and cardiovascular diseases]. *G Ital Cardiol (Rome)*. 2015;16(1):16-20.
15. Frostegård J. Prediction and management of cardiovascular outcomes in systemic lupus erythematosus. *Expert Rev Clin Immunol*. 2015;11(2):247-53.
16. Bahrehmand F, Vaisi-Raygani A, Kiani A, Rahimi Z, Tavilani H, Ardalan M, et al. Matrix metalloproteinase 9 polymorphisms and systemic lupus erythematosus: correlation with systemic inflammatory markers and oxidative stress. *Lupus*. 2014 Nov 21. Epub ahead of print.
17. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. *Semin Arthritis Rheum*. 2013;43(1):77-95.
18. Klumb EM, Silva CA, Lanna CC, Sato EI, Borba EF, Brenol JC, et al. [Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis]. *Rev Bras Reumatol*. 2015;55(1):1-21.
19. Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. *J Cardiovasc Pharmacol*. 2013;62(3):255-62.
20. Denas G, Jose SP, Bracco A, Zoppellaro G, Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. *Autoimmun Rev*. 2015;14(3):214-22.
21. Fernández de Larrinoa RF. What is new in systemic lupus erythematosus. *Rheumatol Clin*. 2015;11(1):27-32.
22. Huang BT, Yao HM, Huang H. Left ventricular remodeling and dysfunction in systemic lupus erythematosus: a three-dimensional speckle tracking study. *Echocardiography*. 2014;31(9):1085-94.
23. Yip GW, Shang Q, Tam LS, Zhang Q, Li EK, Fung JW, et al. Disease chronicity and activity predict subclinical left ventricular systolic dysfunction in patients with systemic lupus erythematosus. *Heart*. 2009;95(12):980-7.

24. Rossi M, Mosca M, Tani C, Franzoni F, Santoro G, Bombardieri S. Integrated backscatter analysis of carotid intima-media complex in patients with systemic lupus erythematosus. *Clin Rheumatol.* 2008;27(12):1485-8.
25. Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. *J Rheumatol.* 2008;35(7):1300-6.
26. Płazak W, Gryga K, Sznajd J, Pasowicz M, Musiał J, Podolec P. Myocardial ischaemia in systemic lupus erythematosus: detection and clinical relevance. *Kardiol Pol.* 2011;69(11):1129-36.
27. Felix RCM, Gouvea CM, Carneiro MP, Mesquita CT. Tomografia computadorizada por emissão de pósitrons nas doenças cardiovasculares inflamatórias. *Arq Bras Cardiol: imagem cardiovasc.* 2014;27(4):249-59.
28. Ozawa K, Funabashi N, Daimon M, Takaoka H, Takano H, Uehara M, et al. Determination of optimum periods between onset of suspected acute myocarditis and 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory left ventricular myocardium. *Int J Cardiol.* 2013;169(3):196-200.
29. Mavrogeni S. Myocarditis in systemic diseases and the role of cardiovascular magnetic resonance. *Hellenic J Cardiol.* 2012;53(2):142-7.
30. Mavrogeni S, Karabela G, Stavropoulos E, Plastiras S, Spiliotis G, Gialafos E, et al. Heart failure imaging patterns in systemic lupus erythematosus. Evaluation using cardiovascular magnetic resonance. *Int J Cardiol.* 2014;176(2):559-61.
31. Croca SC, Rahman A. Imaging assessment of cardiovascular disease in systemic lupus erythematosus. *Clin Dev Immunol.* 2012;2012:694143.

۳. تاثیرات طرح تحول سلامت بر بخش فیزیوتراپی در ایران: مطالعه ای کیفی با بهره گیری از پنچ اهرم کنترلی

1. Behzadifar M, Behzadifar M, Bakhtiari A, et al. The effect of the health transformation plan on cesarean section in Iran: a systematic review of the literature. *BMC Res Notes.* 2019; 12(1):37.
2. Moradi-Lakeh M, Vosoogh-Moghaddam A. Health sector evolution plan in Iran; equity and sustainability concerns. *Int J Health Policy Manag.* 2015;4(10):637–640.

3. Piroozi B, Rashidian A, Moradi G, et al. Out-of-pocket and informal payment before and after the health transformation plan in Iran: evidence from hospitals located in Kurdistan, Iran. *Int J Health Policy Manag.* 2017;6(10):573–586.
4. Yazdi-Feyzabadi V, Mehrolohasani MH, Darvishi A. Measuring catastrophic health expenditures and its inequality: evidence from Iran's Health Transformation Program. *Health Policy Plan.* 2019;34(4):316–325.
5. Doshmangir L, Bazayr M, Najafi B, et al. Health financing consequences of implementing health transformation plan in Iran: achievements and challenges. *Int J Health Policy Manag.* 2019;8(6):384–386.
6. World Health Organization. *Rehabilitation in health systems: guide for action.* Geneva (Switzerland): World Health Organization; 2019.
7. Khammarnia M, Barfar E, Ansari-Moghadam A, et al. The households health spending and impoverishment: a study after Iran's health transformation plan. *Health Scope.* 2018;7(S):e62316.
8. Zarei E, Nikkhah A, Pouragha B. Utilization and out of pocket (OOP) payment for physiotherapy services in public hospitals of Shahid Beheshti University of Medical Sciences. *Med J Islam Repub Iran.* 2018;32(19):1–6.
9. Statistical Center of Iran [Internet]. Tehran (Iran): SCI; 2020 [cited 2020 July 01]. Available from: <https://www.amar.org.ir/english/Statistics-by-Topic/National-accounts>
10. Shahabi S, Shabaninejad H, Kamali M, et al. The effects of ankle foot orthoses on walking speed in patients with stroke: a systematic review and meta-analysis of randomized controlled trials. *Clin Rehabil.* 2020;34(2):145–159.
11. Shahabi S, Rezapour A, Arabloo J. Economic evaluations of physical rehabilitation interventions in older adults with hip and/or knee osteoarthritis: a systematic review. *Eur J Physiother.* 2019. DOI:10.1080/21679169.2019.1672785
12. Renfrew L, Paul L, McFadyen A, et al. The clinical-and cost- effectiveness of functional electrical stimulation and ankle-foot orthoses for foot drop in Multiple Sclerosis: a multicentre randomized trial. *Clin Rehabil.* 2019;33(7):1150–1162.
13. Abdi K, Arab M, Rashidian A, et al. Exploring barriers of the health system to rehabilitation services for people with disabilities in Iran: a qualitative study. *Electron Physician.* 2015;7(7):1476–1485.

14. Soltani S, Takian A, Sari AA, et al. Financial barriers to access to health services for adult people with disability in Iran: the challenges for universal health coverage. *Iran J Public Health*. 2019;48(3):508–515.
15. Shahabi S, Ahmadi Teymourlouy A, Shabaninejad H, et al. Financing of physical rehabilitation services in Iran: a stakeholder and social network analysis. *BMC Health Serv Res*. 2020;20:599.
16. Mirzaie M, Darabi S. Population aging in Iran and rising health care costs. *Iran J Ageing*. 2017;12(2):156–169.
17. Khorrami Z, Rezapour M, Etemad K, et al. The patterns of non communicable disease multimorbidity in Iran: a multilevel analysis. *Sci Rep*. 2020;10(1):1–11.
18. Moradi-Lakeh M, Forouzanfar MH, Vollset SE, et al. Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990–2013: findings from the Global Burden of Disease Study 2013. *Ann Rheum Dis*. 2017;76(8):1365–1373.
19. Bazargan-Hejazi S, Ahmadi A, Shirazi A, et al. The burden of road traffic injuries in Iran and 15 surrounding countries: 1990–2016. *Arch Iran Med*. 2018;21(12):556–565.
20. Stucki G, Bickenbach J, Melvin J. Strengthening rehabilitation in health systems worldwide by integrating information on functioning in national health information systems. *Am J Phys Med Rehabil*. 2017;96(9):677–681.
21. Roberts M, Hsiao W, Berman P, et al. Getting health reform right: a guide to improving performance and equity. Oxford (UK): Oxford University Press; 2003.
22. Bielykh A, Pylypchuk A, Moiseieva A. Health reforms in Romania: Harvard flagship approach. *Modern Econ Stud*. 2018;1(1):42–50.
23. Braun V, Clarke V. Thematic analysis. In: *APA handbook of research methods in psychology*. Vol. 2. Research designs: Quantitative, qualitative, neuropsychological, and biological. Washington (DC): American Psychological Association; 2012.
24. Gemignani M. Toward a critical reflexivity in qualitative inquiry: relational and posthumanist reflections on realism, researcher's centrality, and representationalism in reflexivity. *Qual Psychol*. 2017;4(2):185–198.
25. Kyng as H, K ari ainen M, Elo S. The trustworthiness of content analysis. In: *The Application of Content Analysis in Nursing Science Research*. Berlin (Germany): Springer; 2020. p. 41–48.

26. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19(6):349–357.
27. O'Brien BC, Harris IB, Beckman TJ, et al. Standards for reporting qualitative research: a synthesis of recommendations. *Acad Med*. 2014;89(9):1245–1251.
28. World Health Organization. *Implementing health financing reform: lessons from countries in transition*. Geneva (Switzerland): World Health Organization; 2010.
29. Babashahy S, Baghbanian A, Manavi S, et al. Insight into provider payment mechanisms in healthcare industry: a case of Iran. *Iran J Public Health*. 2016;45(5):693–695.
30. Bornhöft L, Larsson ME, Thorn J. Physiotherapy in primary care Triage - the effects on utilization of medical services at primary health care clinics by patients and sub-groups of patients with musculoskeletal disorders: a case-control study. *Physiother Theory Pract*. 2015;31(1):45–52.
31. Mosadeghrad AM, Mirzaee N, Afshari M, et al. The impact of health transformation plan on health services fees: brief report. *Tehran Univ Med J*. 2018;76(4):277–282.
32. Yousefvand M, Olyaeemanesh A, Arab M, et al. The behavior of basic health insurance organizations after the implementation of relative value of health services book in Iran: a qualitative study. *Med J Islam Repub Iran*. 2018;32:110.
33. Ferdosi M, Kabiri S, Keyvanara M, et al. Challenges of Iran health transformation plan about inpatients payment: viewpoint of experts. *Health Scope*. 2017;6(3):e14388.
34. Doshmangir L, Sajadi HS, Ghiasipour M, et al. Informal payments for inpatient health care in post-health transformation plan period: evidence from Iran. *BMC Public Health*. 2020;20:1–14.
35. Factor R, Kang M. Corruption and population health outcomes: an analysis of data from 133 countries using structural equation modeling. *Int J Public Health*. 2015;60(6): 633–641.
36. Harris MF, Chan BC, Daniel C, et al. Development and early experience from an intervention to facilitate teamwork between general practices and allied health providers: the Team-link study. *BMC Health Serv Res*. 2010;10(1):104.
37. Doshmangir L, Rashidian A, Jafari M, et al. Opening the black box: the experiences and lessons from the public hospitals autonomy policy in Iran. *Arch Iran Med*. 2015; 18(7):416–424.

38. Markazi-Moghaddam N, Aryankhesal A, Arab M. The first stages of liberalization of public hospitals in Iran: establishment of autonomous hospitals and the barriers. *Iran J Public Health*. 2014;43(12):1640–1650.
39. Karimi A, Nateghian A. Medical education and autonomy in teaching hospitals. *Indian J Med Ethics*. 2002;2:33–34.
40. Al Kuwaiti A, Al Muhanna FA. Challenges of privatizing academic medical centers in Saudi Arabia and appropriate strategies for implementation. *Int J Health Gov*. 2020; 25(1): 68–77.
41. McVeigh J, MacLachlan M, Gilmore B, et al. Promoting good policy for leadership and governance of health related rehabilitation: a realist synthesis. *Global Health*. 2016;12(1):49.

۴. بررسی تاثیر آفت کش ها بر سلامت روانی کارکنان در معرض خطر - ایران

1. Sankhla MS, Kumari M, Sharma K, Kushwah RS, Kumar RJIJRiAS, Technology E. “Water contamination through pesticide & their toxic effect on human health”. 2018;6(1):967-70.
2. Stallones L, Beseler CLJC. “Assessing the connection between organophosphate pesticide poisoning and mental health: a comparison of neuropsychological symptoms from clinical observations, animal models and epidemiological studies”. 2016;74:405-16.
3. Stallones L, Doenges T, Dik BJ, Valley MAJAjoim. “Occupation and suicide: Colorado”, 2004–2006.
4. Levin HS, Rodnitzky RLJCt. “Behavioral effects of organophosphate pesticides in man”. 1976;9(3):391-405.
5. Alavanja MC, Hoppin JA, Kamel FJARPH. “Health effects of chronic pesticide exposure: cancer and neurotoxicity”. 2004;25:155-97.
6. Khan N, Kennedy A, Cotton J, Brumby SJIjoer, health p. “A pest to mental health? Exploring the link between exposure to agrichemicals in farmers and mental health”. 2019;16(8):1327.
7. Harrison V, Ross SMJEr. “Anxiety and depression following cumulative low-level exposure to organophosphate pesticides”. 2016;151:528-36.
8. Kim K-H, Kabir E, Jahan SAJSofTE. “Exposure to pesticides and the associated human health effects”. 2017;575:525-35.

9. Terziev V, Petkova-Georgieva SJIE-JoAiSS. "Human Health Problems and Classification of the Most Toxic Pesticides". 2020;5(15):1349-56.
10. Damalas CA, Eleftherohorinos IGJJoer, health p. "Pesticide exposure, safety issues, and risk assessment indicators". 2011;8(5):1402-19.
11. Terziev V, Petkova-Georgieva SJIE-JoAiSS. "The pesticides toxic impact on the human health condition and the ecosystem". 2020;5(15):1314-20.
12. Margni M, Rossier D, Crettaz P, Jolliet OJA, ecosystems, environment. "Life cycle impact assessment of pesticides on human health and ecosystems". 2002;93(1-3):379-92.
13. Beard JD, Umbach DM, Hoppin JA, Richards M, Alavanja MC, Blair A, et al. "Pesticide exposure and depression among male private pesticide applicators in the agricultural health study". 2014;122(9):984-91.
14. Reza PA, Aziz SV, Ali MA, Marjan MH, Reza TMJAjots. "Evaluation of knowledge of healthcare workers in hospitals of Zabol city on proper methods of blood and components transfusion". 2009;3(2):78.
15. Kim J, Ko Y, Lee WJJO, medicine e. "Depressive symptoms and severity of acute occupational pesticide poisoning among male farmers". 2013;70(5):303-9.
16. Rani L, Thapa K, Kanojia N, Sharma N, Singh S, Grewal AS, et al. "An extensive review on the consequences of chemical pesticides on human health and environment". 2020:124657.

۵. فروزن سکشن

- 1- Rosai Juan. Ackerman's Surgical Pathology. 8th ed. Missouri: Mosby; 2017. Introduction: Frozen Section;
- 2- Hasnan Jaafar. Intra-Operative Frozen Section Consultation: Concepts, Applications and Limitations. Malays J Med Sci. 2006 Jan; 13(1): 4-12.

۶. جایگاه امروز HIPEC

1. Thomassen I, van Gestel YR, Lemmens VE, de Hingh IH. Incidence, prognosis, and treatment

options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin
Dis Colon Rectum. 2013;56(12):1373–80.

2. Neuwirth MG, Alexander HR, Karakousis GC. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. *J Gastrointest Oncol*. 2016;7(1):18–28.

3. Bartlett DL. HIPEC: the complexities of clinical trials. *Ann Surg Oncol*. 2008;15(5):1277–9.

4. Meigs JV. *Tumors of the female pelvic organs*. New York: Macmillan; 1934.

5. Sugarbaker PH. Peritonectomy procedures. *Ann Surg*. 1995;221:29–42.

6. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. *Crit Rev OncolHematol*. 2002;43:33–56.

7. Ceelen W, Flessner M. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. *Nat Rev Clin Oncol*. 2009;2010(7):108–15.

8. de Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. *Recent Results Cancer Res*. 2007;169:39–51.

9. de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. *Recent Results Cancer Res*. 2007;169:53–73.

10. de Bree E. Optimal drugs for HIPEC in different tumors. *J BUON*. 2015;20(Suppl 1):S40–6.

11. Piso P, Glockzin G, von Breitenbuch P, Sulaiman T, Popp F, Dahlke M, et al. Patient selection for a curative approach to Carcinomatosis. *Cancer J*. 2009;15(3):236–42.

12. Yan TD, Morris DL, Shigeki K, Dario B, Marcello D. (2008). Preoperative investigations in the management of peritoneal surface malignancy with cyto reductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement. *J Surg Oncol*. 2008;98(4):224–7.

13. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. *Am J Surg Pathol*. 1995;19(12):1390.

14. Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. *Curr Oncol*. 2011;18(2):e84–96.

15. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the locoregional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). *J Surg Oncol.* 2008;98(4):277–82.
16. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. *Ann Surg Oncol.* 2007;14(2):484–92.
17. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. *Ann Surg Oncol.* 1999;6:727–31.
18. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *J Clin Oncol.* 2012;30(20):2449–56.
19. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. On behalf of the French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. *Cancer.* 2010;116:5608–18.
20. Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. *Ann Surg Oncol.* 2013;20:4224–30.
21. Tafampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: analysis of 519 patients. *Eur J Surg Oncol.* 2014;40(5):515–20.
22. Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. *Eur J Surg Oncol.* 2016;42(7):1035–41.
23. Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. *Eur J Surg Oncol.* 2015;41(3):396–9.

24. Delhorme JB, Honoré C, Benhaim L, Dumont F, Dartigues P, Dromain C, et al. Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei. *Eur J Surg Oncol.* 2017;43(1):159–67.
25. Mohamed F, Chang D, Sugarbaker PH. Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination. *J Surg Oncol.* 2003;83:5–12.
26. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. *Ann Oncol.* 2007;18(6):985–90.
27. Sugarbaker PH, Welch LS, Mohammed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. *Surg Oncol Clin N Am.* 2003;12:605–21.
28. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. *J Surg Oncol.* 2011;103:822–31.
29. Manzini Vde P, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, et al. Malignant peritoneal mesothelioma: a multicentre study on 81 cases. *Ann Oncol.* 2010;21:348–53.
30. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. *J Clin Oncol.* 2009;27:6237–42.
31. Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. *Ann Surg Oncol.* 2015;22:1686–93.
32. Malgras B, Gayat E, Aoun O, Lo Dico R, Eveno C, Pautrat K, et al. Impact of combination chemotherapy in peritoneal mesothelioma Hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study. *Ann Surg Oncol.* 2018;25:3271–9.
33. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol.* 2013;20:1093–100.
34. Bijelic L, Stuart OA, Sugarbaker PH. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma. *Gastroenterol Res Pract.* 2012;2012:890450.

35. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). *Eur J Cancer*. 2013;49(15):3140–8.
36. Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessurealt S. Repeat cytoreductive surgery and HIPEC may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. *Ann Surg Oncol*. 2014;21:1480–6.
37. Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, et al. Malignant peritoneal mesothelioma prognostic factors and oncologic outcome analysis. *Ann Surg Oncol*. 2014;21:1159–65.
38. Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. *Surgery*.
39. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. *Br J Surg*. 2002;89(12):1545–50.
40. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. *Br J Surg*. 2012;99:699–705.
41. van Gestel YR, Thomassen I, Lemmens VE, Pruijt JF, van Herk-Sukel MP, Rutten HJ, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. *Eur J Surg Oncol*. 2014;40:963–9.
42. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol*. 2003;21:3737–43.
43. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. *Ann Surg Oncol*. 2008;15:2426–32.
44. Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. *J Surg Oncol*. 2013;107:566–73.
45. Huang CQ, Min Y, Wang SY, Yang XJ, Liu Y, Xiong B, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. *Oncotarget*. 2017;8(33):55657–83.

46. Chua TC, Yan TD, Zhao J, Morris DL. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. *Eur J Surg Oncol.* 2009;35:1299–305.
47. Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. *Eur J Surg Oncol.* 2017;43(1):144–9.
48. Hompes D, D’Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, et al. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. *J Surg Oncol.* 2014;109:527–32.
49. Honoré C, Goéré D, Souadka A, Dumont F, Elias D. Definition of patients presenting a high risk of developing peritoneal Carcinomatosis after curative surgery for colorectal Cancer: a systematic review. *Ann Surg Oncol.* 2012;20(1):183–92.
50. Elias D, Honoré C, Dumont F, Ducreux M, Boige V, Malka D, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. *Ann Surg.* 2011;254:289–93.
51. Gill RS, Al-Adra PD, Nagendram J, Campbell S, Shi X, Haase E, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. *J Surg Oncol.* 2011;104:692–8.
52. Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. *Eur J Surg Oncol.* 2014;40(1):12–26.
53. Zhentian N, Wei L, Chao Y, Liu W, Yao X, Chen M, et al. Meta-analysis of the efficacy and safety of intraperitoneal hyperthermic chemotherapy in the treatment of advanced gastric cancer during operation combined with surgery. *Chin J Gastrointest Surg.* 2016;19(12):1406–13.
54. Gong Y, Wang P, Zhu Z, Zhang J, Huang J, Wang T, et al. Benefits of surgery after NIPS for GC patients with peritoneal metastasis: a meta-analysis. *J Surg Res.* 2019;245:234–43.
55. Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y, et al. The 30-year experience—A meta-analysis of randomised and high-quality non randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. *Eur J Cancer.* 2017;79:1–14.
56. Bhatt A, Glehen O. The role of Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian Cancer: a review. *Indian J Surg Oncol.* 2016;7(2):188–97.

57. Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, et al. Survival benefit of adding Hyperthermic IntraPeritoneal chemotherapy (HIPEC) at the different Timepoints of treatment of ovarian Cancer: review of evidence. *Curr Pharm Des.* 2012;18:3793–803.
58. Fagotti A, Costantini B, Vizzielli G, Perelli F, Ercoli A, Gallotta V, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long term analysis of clinical outcome. *Gynecol Oncol.* 2011;122(2):221–5.
59. Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. *Eur J Surg Oncol.* 2013;39:1435–43.
60. Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, HWR S, RHM H, et al. Hyperthermic intraperitoneal chemotherapy in ovarian Cancer. *N Engl J Med.* 2018;378(3):230–40.
61. Lim MC, Chang S-J, Yoo HJ, Nam B-H, Bristow R, Park S-Y. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. *J Clin Oncol.* 2017;35(15 Suppl):5520.
62. Rossi CR, Casali P, Kusamura S, Baratti D, Deraco M. The consensus statement on the locoregional treatment of abdominal sarcomatosis. *J Surg Oncol.* 2008;98(4):291–4.
63. Potter DA, Glenn J, Kinsella T, Glatstein E, Lack EE, Restrepo C, et al. Patterns of recurrence in patients with high grade soft tissue sarcomas. *J Clin Oncol.* 1985;3:353–66.
64. Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. *Cancer.* 2004;100(9):1943–50.
65. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, et al. Peritoneal Sarcomatosis: is there a subset of patients who may benefit from Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy? *Annals of Surg Oncol.* 2010;17(12):3220–8.
66. Sardi A, Muñoz-Zuluaga CA, Sittig M, Diaz-Montes T. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma. *Clinical Case Rep.* 2018;6(6):1142–52.

67. Sommariva A, Pasquali S, Del Fior P, Montesco MC, Pilati PL, Rastrelli M, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal sarcomatosis: long term outcome from a single institution experience. *Anticancer Res.* 2013;33(9):3989–94.
68. Abu-Zaid A, Azzam A, Abuzaid M, Elhassan T, Albadawi N, Alkhatib L, et al. Cytoreductive surgery plus Hyperthermic intraperitoneal chemotherapy for Management of Peritoneal Sarcomatosis: a preliminary single-center experience from Saudi Arabia. *Gastroenterol Res Pract.* 2016;2016:1–8.
69. Inoue D, Yamamoto M, Sugita G, Kurokawa T, Yoshida Y. Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal dissemination. *Gynecol Oncol Rep.* 2015;13:60–3.
70. Salti GI, Ailabouni L, Undevia S. Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal Sarcomatosis. *Ann Surg Oncol.* 2012;19(5):1410–5.
71. Goéré D, Passot G, Gelli M, Levine EA, Bartlett DL, Sugarbaker PH, et al. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). *Int J Hyperth.*

۷. پکوما - یک نئوپلازم رحمی نادر

1. Pea M, Bonetti F, Zamboni G, et al. Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney. *Pathology.* 1991;23(3):185–188. doi:10.3109/0031302910906356
2. Pea M, Bonetti F, Zamboni G, Martignoni G, Fiore-Donati L, Doglioni C. Clear cell tumor and angiomyolipoma. *Am J Surg Pathol.* 1991;15(2):199–200. doi:10.1097/00000478-199102000-
3. Machado I, Cruz J, Lavernia J, Rayon JM, Poveda A, Llombart-Bosch A. Malignant PEComa with metastatic disease at diagnosis and resistance to several chemotherapy regimens and targeted therapy (mTOR inhibitor). *Int J Surg Pathol.* (2017) 25:543–9. doi: 10.1177/106689691770124
4. Musella A, De Felice F, Kyriacou AK, et al. Perivascular epithelioid cell neoplasm (PEComa) of the uterus: a systematic review. *Int J Surg* 2015;1(19):1–5. doi:10.1016/j.ijssu.2015.05.002
5. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. *Am J Obstet Gynecol.* (2003) 188:100–7. doi: 10.1067/mob.2003.

6. Sadigh S, Shah P, Weber K, Sebro R, Zhang PJ. Primary malignant perivascular epithelioid cell neoplasm (PEComa) of the bone mimicking granular cell tumor in core biopsy: a case report and literature review. *Oncol Lett.* (2018)
7. Conlon N, Soslow RA, Murali R. Perivascular epithelioid tumours (PEComas) of the gynaecological tract. *J Clin Pathol.* (2015) 68:418–26. doi: 10.1136/jclinpath-2015-202945
8. Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, et al. Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas). *Clin Cancer Res.* (2019) 25:5295–300. doi:10.1158/1078-0432.CCR-19-0288.
9. Pan CC, Chung MY, Ng KF, Liu CY, Wang JS, Chai CY, et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. *J Pathol.* (2008) 214:387–93. doi: 10.1002/path.228
10. Bosincu L, Rocca PC, Martignoni G, et al. Perivascular epithelioid cell (PEC) tumors of the uterus: a clinicopathologic study of two cases with aggressive features. *Mod Pathol.* 2005;18(10):1336-1342.
11. Nitahara K, Sasaki M, Ichikawa S, Tsuji K, Yoshida Y. Rupture of perivascular epithelioid cell neoplasm at 34 weeks' gestation: a nonendometriosis case of spontaneous hemoperitoneum in pregnancy. *J Obstet Gynaecol Res.* 2019;45(3):709-713.
12. Fontana E, Savelli L, Alletto A, Seracchioli R. Uterine PEComa initially misdiagnosed as a leiomyoma: Sonographic findings and review of the literature. *J Clin Ultrasound.* 2020;1–6.
13. Prasad SR, Sahani DV, Mino-Kenudson M, et al. Neoplasms of the perivascular epithelioid cell involving the abdomen and the pelvis: cross-sectional imaging findings. *J Comput Assist Tomogr.* 2007;31(5):688–696. doi:10.1097/rct.0b013e318031912f
14. Giannella L, Carpini GD, Montik N, et al. Ultrasound features of a uterine perivascular epithelioid cell tumor (PEComa): case report and literature review. *Diagnostics.* 2020;10(8):553. doi:10.3390/diagnostics10080553
15. Pattamapaspong N, Khunamornpong S, Phongnarisorn C, Pojchamarnwiputh S. Malignant perivascular epithelioid cell tumor of the round ligament mimics leiomyoma on computed tomography. *Singapore Med J.* 2009;50(7):e239–e242.
16. Schoolmeester JK, Howitt BE, Hirsch MS, Dal Cin P, Quade BJ, Nucci MR. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract. *Am J Surg Pathol.* 2014;38(2):176-188.
17. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. *WHO Classification of Tumors of Soft Tissue and Bone.* Fourth ed. IARC Press: Lyon; 2013.

18. Fadare O. Perivascular epithelioid cell tumor (PEComa) of the uterus: an outcome-based clinicopathologic analysis of 41 reported cases. *Adv Anat Pathol*. 2008;15(2):63–75. doi:10.1097/PAP.0b013e31816613b0

19. Jeon IS, Lee SM. Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus. *J Pediatr Hematol Oncol*. 2005;27(12):681–684. doi:10.1097/01.mph.0000193475.06870.d5

20. Vang R, Kempson RL. Perivascular epithelioid cell tumor (PEComa) of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. *Am J Surg Pathol*. 2002;26(1):1–3. doi:10.1097/00000478-200201000-00001

۸. اسکن هسته ای قلب با رادیو داروی ^{123}I -MIBG: دریچه ای از قلب به مغز

1. Aimo, A., & Gimelli, A. (2021). Myocardial innervation imaging: MIBG in clinical practice, Imaging (published online ahead of print 2021). Retrieved Oct 23, 2021, from <https://akjournals.com/view/journals/1647/aop/article-10.1556-1647.2021.00021/article-10.1556-1647.2021.00021.xml>.

2. Chung EJ, Kim SJ. (123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review. *J Mov Disord*. 2015;8(2):55-66. doi:10.14802/jmd.15015.

3. Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, Giordano A. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. *Clin Auton Res*. 2012 Feb;22(1):43-55.

۹. گزارش یک مورد بیمار، با درد ناتوان کننده ران ناشی از میوزیت موضعی به دنبال ابتلا به کووید

۱۹

1. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. 2020;382(18):1708-20.

2. Lundberg IE, De Visser M, Werth VPJNRR. Classification of myositis. 2018;14(5):269-78.

3. Heffner Jr RR, Armbrustmacher VW, Earle KMJC. Focal myositis. 1977;40(1):301-6.
4. Kransdorf MJ, Temple HT, Sweet DEJSr. Focal myositis. 1998;27(5):283-7.
5. Gefen AM, Palumbo N, Nathan SK, Singer PS, Castellanos-Reyes LJ, Sethna CBJPN. Pediatric COVID-19-associated rhabdomyolysis: a case report. 2020;35(8):1517-20.
6. Moreno-Lugris C, Gonzalez-Gay MA, Sanchez-Andrade A, Blanco R, Basanta D, Ibanez D, et al. Magnetic resonance imaging: a useful technique in the diagnosis and follow up of focal myositis. 1996;55(11):856.
7. Dalakas MCJN-NN. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. 2020;7(5).
8. Beydon M, Chevalier K, Al Tabaa O, Hamroun S, Delette A-S, Thomas M, et al. Myositis as a manifestation of SARS-CoV-2. 2021;80(3):e42-e.
9. Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton DJJocf. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. 2020;26(6):470-5.
10. Crum-Cianflone NFJCMr. Bacterial, fungal, parasitic, and viral myositis. 2008;21(3):473- 4.
11. Naylor CD, Jevnikar AM, Witt NJCCMAJ. Sporadic viral myositis in two adults. 1987;137(9):819.

۱۰. نقش هایپک پروفیلاکسی در سرطان های کولورکتال

1. Russell AH, Tong D, Dawson LE, Wisbeck WJC. Adenocarcinoma of the proximal colon sites of initial dissemination and patterns of recurrence following surgery alone. 1984;53(2):360-7.
2. Landmann RG, Weiser MRJCic, surgery r. Surgical management of locally advanced and locally recurrent colon cancer. 2005;18(03):182-9.
3. Honoré C, Goéré D, Souadka A, Dumont F, Elias DJAoso. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. 2013;20(1):183-92.
4. Trilling B, Cotte E, Vaudoyer D, Isaac S, Piaton E, Maurice C, et al. Intraperitoneal-free cancer cells represent a major prognostic factor in colorectal peritoneal carcinomatosis. 2016;59(7):615-22.
5. Kyang LS, Valle SJ, Alzahrani NA, Morris DLJAjos. Prevention of peritoneal recurrence in high-risk colorectal cancer and evidence of T4 status as a potential risk factor. 2018;88(10):975-81.
6. Sugarbaker PHJWJoGW. Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. 2014;20(28):9286.

7. Segelman J, Akre O, Gustafsson U, Bottai M, Martling AJCD. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. 2014;16(5):359-67.
8. Segelman J, Akre O, Gustafsson U, Bottai M, Martling AJCD. External validation of models predicting the individual risk of metachronous peritoneal carcinomatosis from colon and rectal cancer. 2016;18(4):378-85.
9. Group FCJTLO. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. 2012;13(11):1152-60.
10. Mokhles S, Macbeth F, Farewell V, Fiorentino F, Williams N, Younes R, et al. Meta-analysis of colorectal cancer follow-up after potentially curative resection. 2016;103(10):1259-68.
11. Ocana A, Díez-González L, García-Olmo DC, Templeton AJ, Vera-Badillo F, Escribano MJ, et al. Circulating DNA and survival in solid tumors. 2016;25(2):399-406.
12. Olmedillas Lopez S, García-Olmo DC, García-Arranz M, Guadalajara H, Pastor C, García-Olmo DJIjoms. KRAS G12V mutation detection by droplet digital PCR in circulating cell-free DNA of colorectal cancer patients. 2016;17(4):484.
13. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe J-M, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. 2009;27(5):681-5.
14. Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? 2013;257(6):1065-71.
15. Klaver C, Groenen H, Morton D, Laurberg S, Bemelman W, Tanis PJCD. research committee of the European Society of Coloproctology. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. 2017;19(3):224-36.
16. Glehen OJC. French Surgical Association: Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1,290 patients. 2010;116:5608-18.
17. Passot G, Vaudoyer D, Cotte E, You B, Isaac S, Gilly FN, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. 2012;256(1):125-9.
18. Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. 2008;33(1):87-93.
19. Sugarbaker PHJIjoso. Second-look surgery for colorectal cancer: revised selection factors and new treatment options for greater success. 2011;2011.
20. Elias D, Honoré C, Dumont F, Ducreux M, Boige V, Malka D, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. 2011;254(2):289-93.

21. Del Moral ÁS, Viejo EP, Romero IM, Caravaca GR, Pérez FPJCE. Systematic second-look surgery plus HIPEC in patients without evidence of recurrence, at high risk of carcinomatosis after colorectal cancer resection. 2018;96(2):96-101.
22. Sammartino P, Sibio S, Biacchi D, Cardi M, Mingazzini P, Rosati M, et al. Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. 2014;29(9):1081-9.
23. Tentes A-AK, Kakolyris S, Pallas N, Korakianitis O, Mavroudis C, Zorbas G, et al. Preliminary results with the use of hyperthermic intraperitoneal intraoperative chemotherapy or systemic chemotherapy in high-risk colorectal cancer patients. 2013;2(01):6-10.
24. Arjona-Sánchez A, Barrios P, Boldo-Roda E, Camps B, Carrasco-Campos J, Martín VC, et al. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intraperitoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. 2018;18(1):1-8.
25. Arjona-Sanchez A, Rufian-Peña S, Sanchez-Hidalgo J, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado JJWjos. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (HIPEC) by minimally invasive approach, an initial experience. 2018;42(10):3120-4.
26. Valle S, Alzahrani N, Alzahrani S, Liauw W, Morris DJJoS. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. 2015;23:176-80.